Beijing SL Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Beijing SL Pharmaceutical has a total shareholder equity of CN¥5.6B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥5.9B and CN¥273.4M respectively. Beijing SL Pharmaceutical's EBIT is CN¥76.0M making its interest coverage ratio -9.5. It has cash and short-term investments of CN¥921.2M.
Key information
0%
Debt to equity ratio
CN¥0
Debt
| Interest coverage ratio | -9.5x |
| Cash | CN¥921.19m |
| Equity | CN¥5.64b |
| Total liabilities | CN¥273.44m |
| Total assets | CN¥5.91b |
Recent financial health updates
No updates
Recent updates
Beijing SL Pharmaceutical (SZSE:002038) Is Increasing Its Dividend To CN¥0.15
Jul 02
Beijing SL Pharmaceutical Co., Ltd.'s (SZSE:002038) Popularity With Investors Is Under Threat From Overpricing
Jun 25Why Beijing SL Pharmaceutical's (SZSE:002038) Shaky Earnings Are Just The Beginning Of Its Problems
Apr 30Beijing SL Pharmaceutical Co., Ltd.'s (SZSE:002038) 25% Price Boost Is Out Of Tune With Earnings
Mar 06Financial Position Analysis
Short Term Liabilities: 002038's short term assets (CN¥2.2B) exceed its short term liabilities (CN¥204.6M).
Long Term Liabilities: 002038's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥68.9M).
Debt to Equity History and Analysis
Debt Level: 002038 is debt free.
Reducing Debt: 002038 has no debt compared to 5 years ago when its debt to equity ratio was 0.05%.
Debt Coverage: 002038 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 002038 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 17:22 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Beijing SL Pharmaceutical Co., Ltd. is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| YANG QIAO | Changjiang Securities Co. LTD. |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Jing Qiang | China International Capital Corporation Limited |